Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BLA
Biotech
Replimune's stock spikes 100% on FDA acceptance of resubmission
The FDA expects to make an approval decision on or before April 10, according to Replimune.
Gabrielle Masson
Oct 20, 2025 5:33pm
Cash-strapped Sangamo seeks partner for new gene therapy
Jun 24, 2025 11:53am
Orca prepares to make market plunge after phase 3 win
Mar 17, 2025 7:00am
Omeros stock up after data analysis spurs BLA resubmission plan
Dec 19, 2024 10:54am
Biogen tests FDA with controversial aducanumab filing
Jul 8, 2020 10:55am
Troubled Immunomedics tries again at FDA after rejection
Dec 5, 2019 7:20am
